Abstracts Archive - Page 400 of 2607 - ACR Meeting Abstracts

Abstract Number: 1123 • ACR Convergence 2023
Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016
John Botson¹, Qianhong Fu², Kaiding Zhu², Lissa Padnick-Silver² and Brian LaMoreaux², ¹Orthopedic Physicians Alaska, Anchorage, AK, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Pegloticase can treat uncontrolled gout but anti-drug antibodies limit urate-lowering response and put patients at risk for infusion reactions (IRs).1, 2 The first case…
Abstract Number: 1277 • ACR Convergence 2023
Relationship Between Quality of Life and the Region of the Affected Joints in Japanese Patients with Rheumatoid Arthritis: A Cross-sectional Study
Kenichiro Tokunaga¹, Takahiro Nishino², Hideto Oshikawa¹, Toshihiro Matsui³ and Shigeto Tohma⁴, ¹Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan, ³NHO Sagamihara National Hospital, Kanagawa, Japan, ⁴NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: This clinical study aimed to investigate the relationship between affected joints and the quality of life (QOL) in patients with rheumatoid arthritis (RA) in…
Abstract Number: 1302 • ACR Convergence 2023
Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study
Daniel Solomon¹, Olga Demler², Pamela Rist², Leah Santacroce¹, Jon Giles³, Katherine Liao¹ and Joan Bathon³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Columbia University, New York, NY
Background/Purpose: Cardiovascular (CV) disease remains an important source of morbidity and the most common cause of mortality in patients with rheumatoid arthritis (RA). It has…
Abstract Number: 1307 • ACR Convergence 2023
Impact of Comorbidities on the First bDMARD Effectiveness and Retention Rate After 2 Years of Follow-up in Patients with Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER
Clementina López Medina¹, Jerusalem Calvo², Lucia Otero-Valera³, Alejandro Escudero Contreras², Rafaela Ortega Castro⁴, Lourdes Ladehesa Pineda⁵, Cristina Campos⁶, Pilar Bernabeu-Gonzálvez⁷, Cristina Bohorquez⁸, Alicia Garcia Dorta⁹, Dolores Ruiz-Montesinos¹⁰, Manuel Enrique Pombo Suarez¹¹, Inmaculada Ros¹², Fernando Alonso³ and Isabel Castrejon¹³, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ²Reina Sofia University Hospital, Córdoba, Spain, ³Spanish Society of Rheumatology, Madrid, Spain, ⁴Hospital Reina Sofía, Cordoba, Spain, ⁵Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ⁶Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁷General University Hospital Dr. Balmis, Alicante, Spain, ⁸Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ⁹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹¹Hospital Clínico Universitario, Santiago de Compostela, Spain, ¹²Rheumatology Department HUSLL, Palma de Mallorca, Spain, ¹³Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of comorbidities, compared to the general population. The presence of such comorbidities has been directly…
Abstract Number: 1309 • ACR Convergence 2023
Refractory RA Patients for Targeted Therapies in Real Life
Elena Grau Garcia¹, Laura Mas Sanchez², Pablo Francisco Muñoz Martínez³, Carmen Riesco Barcena¹, Alba Maria Torrat Noves¹, Daniel Ramos Castro¹, Anderson Victor Huaylla Quispe¹, Iago Alcantara Alvarez¹, Belen Villanueva Mañez¹, Ernesto Tovar Sugrañes¹, Elvira Vicens Bernabeu¹, Hikmat Charia¹, Marta De la Rubia Navarro², Luis Gonzalez Puig¹, Jose Ivorra Cortes¹, Samuel Leal Rodriguez¹, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Ines Canovas Olmos¹, Carmen Najera Herranz¹ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valéncia, Spain, ³Rheumatology Department. HUP La Fe, Sagunto, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Despite the increasing number of available targeted therapies (TT) in rheumatoid arthritis (RA), a proportion of RA patients fail to respond to their first…
Abstract Number: 1296 • ACR Convergence 2023
Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study
Bradly Kimbrough¹, Cynthia Crowson¹, John Davis¹, Eric Matteson² and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN
Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…
Abstract Number: 1287 • ACR Convergence 2023
Impact of Body Mass Index (BMI) on Rheumatoid Arthritis Disease Activity and Musculoskeletal Ultrasound Measures
Nicolette Morris¹, Elena Saab², Lucia Chen¹, Jenny Brook¹, Gurjit S Kaeley³, David Elashoff¹ and Veena Ranganath¹, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Wake Forest University School of Medicine, Los Angeles, CA, ³University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Rheumatoid arthritis (RA) patients with obesity are less likely to respond to therapy and achieve remission. Obesity is a known driver of inflammatory processes…
Abstract Number: 1316 • ACR Convergence 2023
Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis
Ana Martinez Feito¹, Chamaida Plasencia-Rodríguez², Marta Novella-Navarro², Johanna E. Gehin³, Borja Hernandez-Breijo⁴, Claudia M.Brenis⁵, Alejandro Villalba⁶, Elisa Fernandez-Fernandez⁴, Irene Monjo⁷, Dora Pascual-Salcedo⁸, Pilar Nozal⁹ and Alejandro Balsa², ¹Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴La Paz University Hospital, Madrid, Spain, ⁵VIB-UGent Inflammation Research Center Gent, Belgium, Gent, Belgium, ⁶Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁷University Hospital La Paz, Madrid, Spain, ⁸Immuno-Rheumatology Research Group, La Paz University Hospital, Madrid, Spain, ⁹Immunology Unit in La Paz University Hospital-Idipaz, Madrid, Spain
Background/Purpose: Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity. A significantly lower efficacy of TNF inhibitors (TNFi)…
Abstract Number: 1135 • ACR Convergence 2023
The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients
Alice Kwon¹, Audrey Liu¹, Sonali Narain², Elena Katzap³ and Galina Marder², ¹Northwell Health, Manhasset, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Northwell Health, Great NY, NY
Background/Purpose: Cardiac sarcoidosis is one of the most common causes of mortality from sarcoidosis. In this retrospective study, we describe prescribing patterns and compare outcomes between patients treated with conventional immunosuppressive therapies…
Abstract Number: 1279 • ACR Convergence 2023
What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference
Max Teuwen¹, Salima van Weely¹, Thea Vliet Vlieland², Thom Douw³, Manja van Wissen¹, Alfons den Broeder⁴, Dirkjan van Schaardenburg⁵, Cornelia van den Ende⁴ and Maaike gademan¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leids University Medical Center, Leiden, Netherlands, ³Leiden University of Applied Sciences, Leiden, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: There is a lack of knowledge about the limitations in activities and participation experienced by a subgroup of people with rheumatoid arthritis (RA) and…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 1301 • ACR Convergence 2023
The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis
Maryam Adas¹, Sam Norton¹, Andrew Cope¹, Maya Buch², James Galloway¹ and Elena Nikiphorou¹, ¹King's College London, London, United Kingdom, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Psychosocial factors may interplay with biological factors to drive a refractory disease state in patients with inflammatory arthritis1. We aim to explore which socioeconomic,…
Abstract Number: 1315 • ACR Convergence 2023
Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies
Elena Zonova¹, Antonio Abbate², Eugen Feist³, Sergey Yakushin⁴, Maria Lemak⁵, Alina Egorova⁵, Daria Bukhanova⁵, Sergey Grishin⁵, Sofia Kuzkina⁵, Mikhail Samsonov⁶ and EVGENY NASONOV⁷, ¹Novosibirsk State Medical University, Novosibirsk, Russia, ²Robert M. Berne Cardiovascular Research Center, Charlottesville, VA, ³Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁴Ryazan State Medical University, Ryazan, Russia, ⁵R-Pharm, Moscow, Russia, ⁶RPharm, Moscow, Russia, ⁷Scientific Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Active rheumatoid arthritis (RA) is associated with a higher prevalence of insulin resistance (IR). Dysregulation of adipokines driven by low-level systemic inflammation plays a…
Abstract Number: 1243 • ACR Convergence 2023
Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study
Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
Abstract Number: 1145 • ACR Convergence 2023
Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat
Ryan Feaver¹, Scott Bowers², Banumathi Cole¹, Steve Hoang¹, Mark Lawson¹, Justin Taylor¹, Brian LaMoreaux², Lin Zhao², Brad R Henke¹, Brian Johns¹, Andrew C Nyborg², Brian R Wamhoff¹ and Rob Figler¹, ¹HemoShear Therapeutics, Charlottesville, VA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Gout is a chronic inflammatory arthritis that is undertreated and managed with the xanthine oxidase inhibitors febuxostat or allopurinol. Despite the United States Food…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].